Gastrointestinal

Chronic diarrhea: outpatient diagnostic algorithm

Clinical Overview and When to Suspect Chronic Diarrhea

— Acute: <2 weeks (usually infectious); persistent: 2–4 weeks; chronic: >4 weeks

— Distinguish true diarrhea from pseudodiarrhea (frequent small volumes, hallmark of IBS or proctitis) and fecal incontinence (loss of continence, not increased volume)

— Prevalence ~5% of US adults; common reason for ambulatory GI referral

— Step 3 framing: the workup is driven by mechanism, not just symptom severity — categorize early as watery (secretory vs osmotic), fatty (malabsorptive), or inflammatory

— Age >50 with new-onset diarrhea, blood in stool, nocturnal diarrhea waking patient, unintentional weight loss >5%, iron-deficiency anemia, family history of CRC/IBD/celiac, recent antibiotics (C. difficile), recent travel/immunosuppression

— Alarm features mandate colonoscopy rather than empiric IBS treatment

— Confirm chronicity and rule out medication/diet causes before ordering extensive labs

— Sort by mechanism using stool characteristics, timing (fasting test), and basic labs

— IBS-D (most common in <50), IBD, microscopic colitis (older women, NSAID/SSRI users), celiac disease, chronic infections (Giardia), bile acid diarrhea (post-cholecystectomy), lactose intolerance, medications

Step 3 management: Before launching a broad workup, perform a 5-minute medication and diet review — metformin, magnesium, PPIs, SSRIs, colchicine, orlistat, sorbitol/sugar-free gum, and recent antibiotics resolve a surprising fraction of "chronic diarrhea" referrals without further testing.

Definition: decrease in stool consistency (loose/watery) lasting >4 weeks, typically with ≥3 stools/day or stool weight >200 g/day

Epidemiology and outpatient framing:

When to suspect a serious cause (alarm features):

Initial outpatient approach:

Common mechanism distribution in adults:

Presentation Patterns and Key History

— Watery secretory: large volume, persists with fasting, nocturnal, normal osmotic gap → VIPoma, carcinoid, microscopic colitis, bile acid diarrhea

— Watery osmotic: stops with fasting, related to ingestion → lactose intolerance, sorbitol/mannitol, magnesium laxatives, PEG

— Fatty (steatorrhea): greasy, foul-smelling, floats, hard to flush → pancreatic insufficiency, celiac, SIBO, short bowel

— Inflammatory: blood, mucus, tenesmus, fever, urgency → IBD, invasive infection, ischemic colitis, radiation colitis

— Nocturnal diarrhea is organic until proven otherwise (IBD, microscopic colitis, diabetic autonomic neuropathy) — argues strongly against IBS

— Postprandial within 30 min: dumping syndrome, gastrocolic reflex (IBS)

— Post-cholecystectomy or ileal resection: bile acid diarrhea

— Diet: dairy, sugar-free products, gluten, caffeine, FODMAPs

— Medications: metformin, magnesium antacids, PPI, SSRI, NSAIDs, chemotherapy, recent antibiotics (C. diff), ACE inhibitors (rare)

— Travel/exposures: Giardia (hiking, daycare, well water), Cyclospora

— Surgical: cholecystectomy, gastric bypass, ileal resection, pancreatic surgery

— Systemic: thyroid symptoms, flushing (carcinoid), diabetes, HIV risk

— Family history: celiac, IBD, CRC, MEN1

— Hematochezia, weight loss, anemia, age >50, fever, nocturnal symptoms, family history IBD/CRC

Key distinction: IBS-D never causes nocturnal diarrhea, weight loss, anemia, or hematochezia — presence of any of these should redirect the workup toward organic disease and trigger colonoscopy plus targeted labs rather than empiric antispasmodics or low-FODMAP trials.

Categorize by stool quality (most diagnostic single question):

Timing cues:

Targeted history:

Red flags requiring expedited workup:

Physical Exam Findings and Volume Status Assessment

— Orthostatic vitals and weight trend — chronic diarrhea rarely causes acute hypovolemia but volume depletion + AKI can occur with high-output secretory diarrhea (VIPoma, carcinoid)

— BMI trajectory: weight loss suggests malabsorption, IBD, malignancy, hyperthyroidism

— Tachycardia at rest: hyperthyroidism, dehydration, carcinoid

— Dermatitis herpetiformis (pruritic vesicles on extensor surfaces) → celiac disease

— Flushing episodes → carcinoid syndrome

— Hyperpigmentation → Addison disease, Whipple disease

— Erythema nodosum, pyoderma gangrenosum → IBD

— Glossitis, angular cheilitis, pallor → B12/iron/folate deficiency from malabsorption

— Acanthosis nigricans in adult-onset diabetes with diarrhea → consider pancreatic insufficiency

— RLQ mass/tenderness → Crohn ileitis, appendiceal abscess

— Hepatomegaly → metastatic carcinoid, amyloidosis

— Surgical scars (cholecystectomy, bowel resection, bariatric)

— Perianal disease (fistulas, skin tags, abscesses) → Crohn disease

— Peripheral neuropathy → B12 deficiency, celiac, diabetic enteropathy

— Autonomic dysfunction with postural hypotension and gastroparesis → diabetic autonomic neuropathy

Board pearl: Perianal fistulas or skin tags in a young patient with chronic diarrhea = Crohn disease until proven otherwise; this single physical finding should prompt ileocolonoscopy and MR enterography rather than empiric IBS therapy.

General/vitals:

Skin and mucous membranes:

Thyroid: goiter, lid lag, tremor → hyperthyroidism as cause

Cardiac: right-sided murmurs (tricuspid regurgitation, pulmonary stenosis) → carcinoid heart disease

Abdominal:

Joints/eyes: uveitis, episcleritis, sacroiliitis, arthritis → IBD

Neuro:

Rectal exam: fecal impaction (paradoxical overflow diarrhea in elderly), masses, blood, fistulas, sphincter tone (fecal incontinence)

Diagnostic Workup — Initial Labs and Stool Studies

— CBC: anemia (IBD, celiac, malignancy), eosinophilia (parasites, eosinophilic enteritis, Addison)

— CMP: electrolytes (non-anion gap acidosis from bicarbonate loss, hypokalemia), albumin (protein loss, malnutrition), LFTs

— TSH: hyperthyroidism

— Tissue transglutaminase IgA + total IgA (celiac screen) — total IgA needed to exclude IgA deficiency

— CRP/ESR: elevated in IBD, infection, malignancy

— HbA1c: diabetic enteropathy

— HIV testing if risk factors

— Fecal calprotectin or lactoferrin: distinguishes IBD/inflammatory from IBS (cutoff ~50–150 µg/g)

— Fecal occult blood

— Stool culture, C. difficile PCR (if antibiotic exposure or healthcare exposure)

— Giardia antigen (and Cryptosporidium in immunocompromised)

— Stool ova and parasites ×3 if travel/exposure

— Stool electrolytes (Na, K) for fecal osmotic gap when watery diarrhea: gap = 290 − 2×(Na+K)

— <50 mOsm/kg = secretory; >100 mOsm/kg = osmotic

— Stool pH <5.6 → carbohydrate malabsorption (lactose, fructose)

— Qualitative fecal fat (Sudan stain) or quantitative 72-hr fecal fat >7 g/day → steatorrhea

— Fecal elastase <200 µg/g → pancreatic exocrine insufficiency

— ↑Calprotectin + anemia → colonoscopy for IBD

— ⊕TTG-IgA → EGD with duodenal biopsies

— ↓Fecal elastase → pancreatic imaging (CT/MRCP), enzyme replacement trial

— ⊕Giardia antigen → tinidazole or metronidazole

— Osmotic gap, low pH → lactose breath test or empiric lactose-free trial

CCS pearl: Order fecal calprotectin, TTG-IgA with total IgA, CBC, CMP, TSH, and stool studies as your initial outpatient panel — this single batch sorts >70% of chronic diarrhea into IBS vs IBD vs celiac vs infection vs malabsorption tracks.

First-tier labs (all patients with chronic diarrhea):

First-tier stool studies:

Pattern recognition with first-tier results:

Diagnostic Workup — Advanced and Confirmatory Studies

— Indicated for: alarm features, age >45–50 (CRC screening overlap), elevated calprotectin, suspected IBD, suspected microscopic colitis

— Random biopsies of normal-appearing mucosa are mandatory to diagnose microscopic colitis (lymphocytic or collagenous) — endoscopy looks normal grossly

— Direct visualization for IBD extent, ischemic colitis, melanosis coli (laxative abuse)

— Confirm celiac disease (≥4 biopsies from second portion duodenum + ≥1–2 from bulb)

— Evaluate Whipple disease, eosinophilic gastroenteritis, giardiasis, lymphoma

— Lactose hydrogen breath test → lactose intolerance

— Glucose or lactulose breath test → SIBO (post-surgical anatomy, scleroderma, diabetes, opioids)

— Fructose breath test if dietary correlation

— CT or MR enterography for small bowel Crohn, masses, mesenteric ischemia

— CT abdomen with pancreatic protocol for chronic pancreatitis, pancreatic tumors

— Octreotide scan/DOTATATE PET for suspected neuroendocrine tumors

— 24-hr urine 5-HIAA → carcinoid

— Serum chromogranin A, VIP, gastrin, calcitonin, glucagon

— Plasma metanephrines if pheochromocytoma suspected

— Cortisol/ACTH if Addison suspected

— 75SeHCAT scan (not widely available in US) or empiric cholestyramine trial — response confirms diagnosis

— Serum 7α-hydroxy-4-cholesten-3-one (C4) where available

Board pearl: A patient with chronic watery diarrhea, normal colonoscopy gross appearance, but lymphocytic infiltrate on random biopsies = microscopic colitis; first-line therapy is budesonide 9 mg daily, and discontinuing offending drugs (NSAIDs, PPIs, SSRIs) often resolves it.

Colonoscopy with ileal intubation and random biopsies:

Upper endoscopy (EGD) with duodenal biopsies:

Breath testing:

Cross-sectional imaging:

Specialized hormonal/secretory workup (for secretory diarrhea with negative initial workup):

Bile acid diarrhea workup:

Risk Stratification and Diagnostic Algorithm Logic

— No alarm features + age <45 + symptoms meeting Rome IV IBS-D criteria (recurrent abdominal pain ≥1 day/week for 3 months, related to defecation/stool form/frequency) → limited workup: CBC, CRP, TTG-IgA, fecal calprotectin, age-appropriate CRC screening

— Normal labs/calprotectin + Rome IV criteria → diagnose IBS-D, treat empirically

— Inflammatory (↑calprotectin, blood, fever, anemia) → colonoscopy + biopsies

— Fatty/malabsorptive (steatorrhea, weight loss, fat-soluble vitamin deficiency) → fecal elastase, TTG, imaging

— Watery secretory (persists fasting, nocturnal, normal gap) → colonoscopy with biopsies (microscopic colitis), bile acid diarrhea trial, hormonal workup

— Watery osmotic (improves fasting, ↑gap, ↓pH) → dietary trial, breath testing

— Avoid shotgun ordering of expensive hormonal panels in IBS-pattern patients (low pretest probability → high false-positive rate)

— Lactose-free diet × 2 weeks

— Gluten-free diet only after celiac serology (otherwise obscures diagnosis)

— Cholestyramine trial for post-cholecystectomy or ileal resection patients

— Pancreatic enzyme replacement for low elastase

— Rifaximin for suspected SIBO

— Young woman, cramping, alternating bowel habit, no nocturnal symptoms → IBS-D (~90%)

— Older woman, NSAID/PPI/SSRI use, watery nocturnal diarrhea, normal labs → microscopic colitis

— Post-cholecystectomy watery diarrhea → bile acid diarrhea

Step 3 management: Don't order a gluten-free diet trial before checking TTG-IgA — gluten withdrawal normalizes serology and villous architecture, and you lose the ability to diagnose celiac without re-challenge, which patients rarely tolerate.

Step 1 — Rule out functional vs organic:

Step 2 — If organic suspected, classify by mechanism:

Step 3 — Match testing to mechanism rather than ordering everything:

Empiric trials as diagnostic tools:

Pretest probability anchors:

Pharmacotherapy — Mechanism-Directed Treatment

— First-line: loperamide PRN (titrate 2–16 mg/day), dietary modification (low-FODMAP), soluble fiber (psyllium)

— Second-line: rifaximin 550 mg TID × 14 days (refractory IBS-D, can repeat ×2)

— Eluxadoline (mixed μ-agonist/δ-antagonist) — avoid in cholecystectomy patients (pancreatitis risk)

— Alosetron (5-HT3 antagonist) — restricted REMS program (ischemic colitis); women with severe IBS-D

— TCAs (amitriptyline, nortriptyline 10–25 mg qhs) for pain-predominant

— Discontinue NSAIDs, PPIs, SSRIs, ranitidine

— Budesonide 9 mg daily × 6–8 weeks, then taper; high relapse rate

— Bismuth subsalicylate, cholestyramine as alternatives

— Pancrelipase with meals (25,000–50,000 lipase units per meal); titrate

— Fat-soluble vitamin (ADEK) replacement

— PPI co-administration enhances enzyme efficacy

— Cholestyramine 4 g daily–TID, colestipol, or colesevelam

— Separate from other meds by 4 hours (binds drugs)

Board pearl: Loperamide is contraindicated in bloody diarrhea, suspected C. difficile, or febrile invasive enteritis — slowing transit promotes toxin retention and toxic megacolon; symptomatic antimotility is safe only in non-inflammatory chronic diarrhea.

IBS-D:

Microscopic colitis:

IBD: topic-specific (5-ASA, budesonide, biologics — see IBD chunk)

Celiac disease: strict lifelong gluten-free diet; refer to dietitian; screen for nutrient deficiencies (iron, B12, folate, vitamin D, calcium); DEXA scan

Pancreatic exocrine insufficiency:

Bile acid diarrhea:

SIBO: rifaximin 550 mg TID × 14 days; treat underlying motility/anatomic cause

Giardiasis: tinidazole 2 g × 1 (preferred) or metronidazole 250 mg TID × 5–7 days; nitazoxanide alternative

Carcinoid: octreotide LAR for symptom control; surgical resection if localized

Bismuth subsalicylate, loperamide: symptom adjuncts; avoid loperamide in suspected C. difficile or invasive bacterial infection

Procedural and Expanded Pharmacologic Management

— Colonoscopy with random biopsies: mandatory for microscopic colitis diagnosis; therapeutic for IBD stricture dilation

— Capsule endoscopy: small bowel evaluation when CT/MR enterography nondiagnostic; contraindicated with suspected stricture without prior patency capsule

— Double-balloon enteroscopy: targeted small bowel biopsy/intervention

— Rifaximin retreatment: up to 2 additional 14-day courses for symptom recurrence

— Eluxadoline 100 mg BID — avoid if cholecystectomy, alcoholism, sphincter of Oddi dysfunction

— Off-label SSRIs/SNRIs for visceral hypersensitivity

— Peppermint oil enteric-coated capsules (level B evidence)

— Long-term low-dose budesonide 3–6 mg daily

— Immunomodulators (azathioprine, anti-TNF) for steroid-dependent cases

— Octreotide LAR 20–30 mg IM monthly, titrate

— Telotristat (tryptophan hydroxylase inhibitor) added for refractory diarrhea

— Liver-directed therapy (embolization, resection) for hepatic metastases

— PRRT (Lu-177 DOTATATE) for progressive disease

— Loperamide, codeine, octreotide for high-output stoma

— Teduglutide (GLP-2 analog) for short bowel syndrome with intestinal failure

— Parenteral nutrition if <100 cm small bowel

CCS pearl: For recurrent C. difficile diarrhea (≥2 episodes), order fidaxomicin 200 mg BID × 10 days or vancomycin tapered/pulsed regimen; bezlotoxumab (monoclonal antibody) reduces recurrence and FMT is indicated after ≥2 recurrences despite appropriate antibiotic therapy.

Endoscopic procedures (diagnostic + therapeutic):

Refractory IBS-D pharmacology depth:

Microscopic colitis refractory disease:

Carcinoid syndrome stepwise:

VIPoma, gastrinoma: octreotide + surgical resection (refer to MEN1 workup)

Bariatric/short bowel:

Fecal microbiota transplant: established for recurrent C. difficile (≥2 recurrences); investigational for IBD-related diarrhea

Special Populations — Elderly and Renal/Hepatic Impairment

— Fecal impaction with paradoxical overflow diarrhea — common, missed diagnosis; rectal exam mandatory

— Microscopic colitis disproportionately affects women >60 — low threshold for colonoscopy with biopsies

— Ischemic colitis in patients with vascular disease, atrial fibrillation, hypotension

— Higher baseline rates of C. difficile (healthcare exposure, antibiotic use, PPI use)

— Medication review: metformin, magnesium-containing antacids/laxatives, SSRIs, cholinesterase inhibitors, colchicine

— Volume depletion risk is higher — lower physiologic reserve; check orthostatic vitals, BUN/Cr

— New chronic diarrhea + weight loss + anemia in patient >50 → colonoscopy promptly (CRC, ileocecal lymphoma)

— Pancreatic adenocarcinoma may present with steatorrhea and weight loss

— Avoid magnesium-containing antacids/laxatives (accumulation, worsens diarrhea, hypermagnesemia)

— Adjust rifaximin — minimally absorbed, generally safe

— Loperamide: generally safe but caution at high doses (cardiotoxicity)

— Eluxadoline contraindicated in severe hepatic impairment

— Bile acid sequestrants safe in renal disease but may worsen acidosis

— Eluxadoline contraindicated in Child-Pugh B/C

— Rifaximin used therapeutically for hepatic encephalopathy — safe but consider drug interactions

— Octreotide dose adjustment in severe hepatic dysfunction

— Watch for spontaneous bacterial peritonitis in cirrhotic with new diarrhea/fever — paracentesis indicated

— Conduct structured deprescribing — discontinue one suspected agent at a time

— Use Beers Criteria to identify high-risk medications in elderly

Step 3 management: In an elderly nursing home patient with chronic diarrhea, always do a rectal exam first to exclude fecal impaction with overflow incontinence before initiating any antidiarrheal — loperamide in this scenario worsens impaction and can precipitate obstruction or perforation.

Elderly considerations:

Cancer risk:

Renal impairment:

Hepatic impairment:

Polypharmacy:

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— Chronic diarrhea in pregnancy is uncommon — consider IBD flare, celiac, hyperthyroidism (hyperemesis-like with diarrhea), infection

— Imaging: avoid CT/fluoroscopy; MR enterography without gadolinium preferred for IBD evaluation

— Endoscopy: flexible sigmoidoscopy without sedation if needed; full colonoscopy reserved for urgent indications, ideally second trimester

— Safe medications: loperamide (category B, limit use), psyllium, mesalamine, budesonide, sulfasalazine (with folate supplementation)

— Avoid: methotrexate (teratogenic), tofacitinib, eluxadoline (limited data), bismuth subsalicylate (third trimester — salicylate)

— Untreated celiac increases risk of low birth weight, miscarriage — adhere to gluten-free diet

— Toddler's diarrhea (chronic nonspecific diarrhea of childhood) — normal growth, resolves

— Celiac disease — failure to thrive, abdominal distention, irritability

— Cystic fibrosis — steatorrhea + recurrent pulmonary infections; sweat chloride test

— Cow's milk protein allergy in infants

— Very early-onset IBD (<6 years) — consider immunodeficiency workup

— Expanded differential: Cryptosporidium, Microsporidia, Isospora, CMV colitis, MAC, HIV enteropathy

— Stool studies for opportunistic pathogens (modified acid-fast stain for crypto/cyclospora)

— Lower threshold for colonoscopy with biopsies (CMV inclusions)

— CD4 <100 → expand to MAC, CMV, microsporidia

— Initiate or optimize ART for HIV enteropathy

— Dumping syndrome (early/late), bile acid diarrhea, SIBO, vitamin/mineral deficiencies, pancreatic insufficiency

Board pearl: In a young child with chronic steatorrhea, recurrent sinopulmonary infections, and failure to thrive, order a sweat chloride test — cystic fibrosis presents with pancreatic exocrine insufficiency in >85% of cases and is part of newborn screening.

Pregnancy:

Pediatric considerations (referred to GI):

Immunocompromised (HIV, transplant, chemotherapy):

Post-bariatric surgery:

Complications and Adverse Outcomes

— Hypokalemia → muscle weakness, arrhythmias, ileus (paradoxically worsens motility issues)

— Non-anion gap metabolic acidosis from bicarbonate loss in stool

— Hypomagnesemia → tetany, arrhythmias, refractory hypokalemia

— Dehydration and prerenal AKI — particularly secretory diarrhea (VIPoma, carcinoid, high-output stoma)

— Hyponatremia from secretory losses

— Iron deficiency anemia (celiac, IBD, occult bleeding)

— Vitamin B12 deficiency (ileal disease, SIBO, pancreatic insufficiency, post-gastric bypass)

— Folate deficiency (celiac, sulfasalazine, methotrexate)

— Fat-soluble vitamin deficiency (ADEK) in steatorrhea → night blindness (A), osteomalacia (D), neuropathy/hemolysis (E), coagulopathy (K)

— Protein-losing enteropathy → edema, hypoalbuminemia

— Calcium/vitamin D deficiency → osteoporosis (especially celiac, IBD)

— Zinc, magnesium deficiency

— IBD: strictures, fistulas, abscesses, toxic megacolon, CRC (surveillance after 8 years)

— Celiac: enteropathy-associated T-cell lymphoma (EATL), small bowel adenocarcinoma, refractory celiac

— Microscopic colitis: rarely perforation; mostly QOL impact

— Carcinoid: right-sided valvular heart disease, mesenteric fibrosis, carcinoid crisis

— Chronic pancreatitis: pancreatic cancer, pseudocysts, diabetes

— Social isolation, depression, work absenteeism (especially IBS-D)

— Skin breakdown, perianal dermatitis

— Long-term cholestyramine: fat-soluble vitamin deficiency, drug binding

— Long-term budesonide: less systemic effect but possible adrenal suppression, osteoporosis

— Loperamide overdose: QT prolongation, torsades

Key distinction: Refractory celiac disease (persistent symptoms despite strict gluten-free diet ≥12 months) requires evaluation for enteropathy-associated T-cell lymphoma with capsule endoscopy, flow cytometry of intraepithelial lymphocytes, and CT/MR enterography — not simply more dietary counseling.

Volume and electrolyte complications:

Nutritional complications:

Disease-specific complications:

Psychosocial:

Medication complications:

When to Escalate Care — Referral, Hospitalization, and Consults

— Alarm features (weight loss, blood, anemia, age >50 with new symptoms, nocturnal diarrhea)

— Elevated fecal calprotectin

— Positive celiac serology requiring confirmatory EGD

— Suspected microscopic colitis (need colonoscopy with biopsies)

— Refractory IBS-D despite first-line therapy

— Suspected neuroendocrine tumor or other rare cause

— Need for capsule endoscopy or enteroscopy

— Severe volume depletion / AKI unresponsive to oral hydration

— Severe electrolyte derangement (K <2.5, severe hyponatremia, symptomatic hypomagnesemia)

— Suspected toxic megacolon (fever, tachycardia, abdominal distention, colonic dilation >6 cm) — surgical and GI consult, NPO, IV steroids if IBD-related

— Severe IBD flare requiring IV steroids/biologic induction

— Suspected mesenteric ischemia

— C. difficile fulminant colitis (hypotension, ileus, megacolon, WBC >15k, lactate >2.2)

— Inability to tolerate PO

— Toxic megacolon, perforation, abscess

— IBD complications (strictures, fistulas refractory to medical therapy)

— Localized carcinoid, VIPoma, gastrinoma

— Short bowel evaluation

— Endocrinology: carcinoid, VIPoma, MEN1 workup, refractory hyperthyroidism

— Infectious disease: persistent parasitic infection, opportunistic infection in immunocompromised, recurrent C. difficile

— Nutrition/dietitian: celiac, IBD, short bowel, fat-soluble vitamin deficiency

— Rheumatology: scleroderma-related SIBO, autoimmune overlap

— Hemodynamic instability, severe acidosis, peritonitis, sepsis from gut translocation, toxic megacolon with impending perforation

CCS pearl: In suspected toxic megacolon, immediately order NPO, IV fluids, IV methylprednisolone (if IBD), broad-spectrum antibiotics, abdominal X-ray, CBC/lactate, surgical consult, and GI consult — and stop all antimotility agents and opioids which precipitate the condition.

Outpatient GI referral indicated for:

Inpatient admission criteria:

Surgical consultation:

Subspecialty referrals:

ICU triage:

Key Differentials — Within the Diarrhea Category

— Microscopic colitis (lymphocytic/collagenous) — older women, NSAID/PPI/SSRI link

— Bile acid diarrhea — post-cholecystectomy, ileal resection, idiopathic

— Neuroendocrine tumors: VIPoma (WDHA syndrome), carcinoid, gastrinoma (Zollinger-Ellison), medullary thyroid cancer (calcitonin)

— Stimulant laxative abuse (senna, bisacodyl) → melanosis coli on colonoscopy

— Addison disease (hyperpigmentation, hyperkalemia, hyponatremia)

— Diabetic autonomic enteropathy

— Chronic infection: Giardia, Cryptosporidium, Cyclospora, HIV enteropathy

— Lactose intolerance (most common)

— Fructose, sorbitol, mannitol malabsorption

— Magnesium-containing antacids/laxatives, PEG

— Other disaccharidase deficiencies (sucrase-isomaltase)

— IBD (Crohn, ulcerative colitis)

— Microscopic colitis can sometimes blur this category

— Ischemic colitis (postprandial pain, vascular risk factors)

— Radiation colitis (history of pelvic radiation)

— Invasive infection (Shigella, Salmonella, Campylobacter, Yersinia, E. histolytica, C. difficile)

— Celiac disease

— Chronic pancreatitis / pancreatic insufficiency (alcohol, CF, autoimmune)

— SIBO (post-surgical, scleroderma, motility disorder)

— Tropical sprue, Whipple disease

— Short bowel syndrome

— Bile salt deficiency (cholestasis)

Board pearl: A fasting test that abolishes diarrhea points to osmotic etiology (ingested solute driving water into lumen), while diarrhea that persists during fasting points to secretory etiology — this single bedside maneuver narrows the differential dramatically before any lab is ordered.

Watery secretory diarrhea (large volume, persists fasting, normal gap):

Watery osmotic diarrhea (improves fasting, ↑gap, ↓pH):

Inflammatory diarrhea (blood, mucus, tenesmus, ↑calprotectin):

Fatty/malabsorptive (steatorrhea, weight loss, vitamin deficiency):

Key Differentials — Outside the Diarrhea Category

— Loss of sphincter control rather than increased stool volume

— Causes: childbirth injury, diabetic neuropathy, anal sphincter trauma, spinal cord disease, dementia

— Workup: anorectal manometry, endoanal ultrasound

— Treatment: biofeedback, sphincteroplasty, sacral nerve stimulation

— Elderly, immobile, opioid use, dementia

— Rectal exam diagnostic — hard impacted stool with liquid leakage

— Treatment: manual disimpaction, enemas, then bowel regimen

— Frequent, small-volume stools without true increased water content

— Common in IBS, proctitis, hyperthyroidism

— Hyperthyroidism — increased motility; check TSH

— Diabetes mellitus — autonomic enteropathy, bacterial overgrowth, medication (metformin, GLP-1 agonists)

— Addison disease — diarrhea + hypotension + hyperpigmentation

— Medullary thyroid carcinoma — calcitonin-mediated

— Metformin, GLP-1 agonists, acarbose

— Magnesium-containing medications

— PPIs (microscopic colitis), SSRIs, colchicine

— Antibiotics (direct effect or C. diff)

— Chemotherapy (5-FU, irinotecan, immune checkpoint inhibitors — immune-mediated colitis)

— Orlistat (steatorrhea)

— Mycophenolate, tacrolimus

— Scleroderma (motility, SIBO)

— Amyloidosis

— Sarcoidosis (rare GI involvement)

— Mastocytosis (flushing, diarrhea, urticaria pigmentosa)

— HIV enteropathy

Step 3 management: In any cancer patient on immune checkpoint inhibitors (pembrolizumab, ipilimumab, nivolumab) presenting with chronic diarrhea, urgently work up for immune-mediated colitis — colonoscopy with biopsies, hold the agent, and treat with high-dose corticosteroids; infliximab or vedolizumab for steroid-refractory cases.

Conditions mimicking chronic diarrhea:

Fecal incontinence (not diarrhea):

Fecal impaction with overflow:

Pseudodiarrhea:

Endocrine mimics:

Drug-induced (extensive list):

Systemic disease:

Long-Term Management and Secondary Prevention

— Establish therapeutic relationship; emphasize benign nature

— Sustained low-FODMAP diet (phased reintroduction), regular exercise, stress management, CBT/gut-directed hypnotherapy

— PRN loperamide, scheduled rifaximin courses for flares

— Periodic reassessment for emergent alarm features

— Strict lifelong gluten-free diet — refer to registered dietitian

— Periodic serology (TTG-IgA) at 6 and 12 months, then annually — should normalize

— Screen and replete deficiencies: iron, ferritin, B12, folate, vitamin D, calcium, zinc

— DEXA scan at diagnosis; repeat per osteoporosis guidelines

— Pneumococcal vaccination (functional hyposplenism)

— Screen first-degree relatives

— Maintenance therapy (mesalamine, biologics, immunomodulators per phenotype)

— CRC surveillance colonoscopy starting 8 years after diagnosis, then every 1–3 years

— Bone health monitoring, vaccinations (avoid live vaccines on biologics)

— Skin cancer surveillance on thiopurines/biologics

— Stop offending drugs permanently if possible

— Long-term low-dose budesonide for relapsers

— Bone health monitoring if on chronic steroids

— Lifelong pancrelipase with meals

— Fat-soluble vitamin replacement; DEXA scan

— Diabetes screening (HbA1c annually in chronic pancreatitis)

— Smoking and alcohol cessation

— Long-term cholestyramine/colesevelam; separate from other meds by 4 hours

— Fat-soluble vitamin monitoring

— Octreotide LAR monthly, ± telotristat

— Annual echocardiogram for carcinoid heart disease, 5-HIAA monitoring

— Age-appropriate CRC screening; immunizations; bone density per indication; nutritional counseling

Board pearl: In celiac disease, persistent or rising TTG-IgA after 12 months of gluten-free diet suggests dietary nonadherence (most common) or refractory celiac disease — re-engage the dietitian first, evaluate for refractory disease only after confirming strict adherence.

IBS-D long-term plan:

Celiac disease:

IBD:

Microscopic colitis:

Pancreatic insufficiency:

Bile acid diarrhea:

Carcinoid:

Health maintenance for all:

Follow-Up, Monitoring, and Patient Counseling

— Reassess in 4–6 weeks after starting empiric therapy (loperamide, dietary trial, budesonide) — earlier if alarm symptoms develop

— After diagnostic colonoscopy/EGD: review pathology, reconcile diagnosis, set treatment plan within 2–4 weeks

— Symptom diary, quality-of-life assessment

— Annual reassessment for emergent alarm features

— Mental health screening (anxiety, depression frequently comorbid)

— TTG-IgA at 6 and 12 months, then annually

— Annual CBC, ferritin, B12, folate, vitamin D, calcium, LFTs, TSH (associated thyroid disease)

— DEXA at diagnosis; repeat per osteoporosis schedule

— Repeat EGD if symptoms persist despite GFD

— CRP, fecal calprotectin every 3–6 months

— Therapeutic drug monitoring (anti-TNF trough levels)

— Surveillance colonoscopy schedule

— Clinical follow-up; repeat colonoscopy only if relapsing/refractory

— Fecal elastase periodically; annual ADEK levels, HbA1c, DEXA

— Nutritional status (weight, albumin)

— Periodic BMP in high-output diarrhea, on cholestyramine, on diuretics

— Magnesium and phosphate in chronic diarrhea

— Dietary counseling: dietitian referral for celiac, IBD, low-FODMAP, pancreatic insufficiency

— Skin care for perianal irritation: barrier creams, gentle cleansing

— Adequate hydration with electrolyte solutions

— Medication adherence and recognizing red flags (blood, weight loss, fever)

— Travel precautions, hand hygiene to prevent infectious diarrhea recurrence

— CBT for IBS-D, gut-directed hypnotherapy

— Support groups (CCFA for IBD, celiac foundations)

Step 3 management: For any patient with chronic diarrhea, document a 4–6 week reassessment visit when initiating empiric therapy — failure to improve mandates escalation to colonoscopy/EGD or specialist referral rather than indefinite empiric trials, which delay diagnosis of IBD, celiac, or malignancy.

Initial follow-up cadence:

Disease-specific monitoring:

IBS-D:

Celiac:

IBD:

Microscopic colitis:

Pancreatic insufficiency:

Volume and electrolyte monitoring:

Counseling pearls:

Mental health and QOL:

Ethical, Legal, and Patient Safety Considerations

— Discuss risks (bleeding, perforation ~1:1000, sedation complications, missed lesions), benefits, alternatives (capsule endoscopy, imaging)

— Tailor for elderly with comorbidities — frailty assessment may favor less invasive workup

— Capacity assessment for patients with dementia; involve surrogate per advance directive

— Giardiasis, cryptosporidiosis, salmonellosis, shigellosis, E. coli O157, cyclosporiasis, typhoid, hepatitis A — public health department reporting per state

— Outbreak suspicion (multiple cases linked) requires immediate health department notification

— C. difficile is reportable in some jurisdictions

— Hand-off after colonoscopy or hospitalization: ensure pathology results communicated, medication reconciliation, follow-up scheduled, results-confirmation closure to prevent missed cancers

— Discharge after IBD admission: clear plan for biologic infusions, lab monitoring, when to call

— Test follow-up: track pending serologies, biopsies; failure to close the loop is a top malpractice claim in GI

— Surreptitious laxative use is a recognized cause of chronic diarrhea (anorexia/bulimia)

— Approach nonjudgmentally; involve mental health

— Confidentiality balanced with safety in adolescents

— FMLA documentation for IBD, severe IBS-D

— ADA accommodations for restroom access

— Respect refusal of colonoscopy after informed discussion; document risk and alternative plan

— Vegan/religious dietary preferences in gluten-free planning

— Cost of gluten-free food, biologics — connect to assistance programs

— Language-concordant dietary education

— Loperamide misuse for opioid effect (high-dose abuse → QT prolongation, sudden death) — FDA warning; counsel and monitor

Board pearl: A patient with chronic watery diarrhea, low serum potassium, and melanosis coli on colonoscopy suggests surreptitious stimulant laxative abuse — address sensitively with screening for eating disorders, involve psychiatry, and avoid confrontation that may damage the therapeutic alliance.

Informed consent for endoscopy:

Reportable conditions:

Transitions of care safety:

Eating disorders and laxative abuse:

Workplace and disability accommodations:

Patient autonomy:

Health disparities:

Polypharmacy/medication safety:

High-Yield Associations and Rapid-Fire Facts

— Dermatitis herpetiformis → celiac disease

— Flushing + diarrhea + right-sided heart murmur → carcinoid syndrome

— Watery diarrhea + hypokalemia + achlorhydria (WDHA) → VIPoma

— Recurrent peptic ulcers + diarrhea → Zollinger-Ellison (gastrinoma)

— Post-cholecystectomy watery diarrhea → bile acid diarrhea, treat with cholestyramine

— Older woman + NSAID/PPI use + watery nocturnal diarrhea + normal colonoscopy → microscopic colitis

— Perianal fistulas + chronic diarrhea → Crohn disease

— Steatorrhea + recurrent sinopulmonary infections in child → cystic fibrosis

— Foamy macrophages PAS-positive in lamina propria → Whipple disease (Tropheryma whipplei)

— Cocoa-colored stool + recent hiking/well water → Giardia

— Hyperpigmentation + diarrhea + hyperkalemia + hyponatremia → Addison disease

— Lactose intolerance: ↑osmotic gap, ↓stool pH, improves with fasting

— Carcinoid: ↑urinary 5-HIAA (avoid bananas, pineapples, tomatoes before collection)

— Celiac: HLA-DQ2/DQ8; first-degree relative ~10% risk

— Microscopic colitis: 80% women, average age 60s

— SIBO: scleroderma, diabetes, post-surgical (Roux-en-Y), opioids, PPI

— Gap = 290 − 2×(stool Na + stool K)

— <50 = secretory; >100 = osmotic

— Metformin, magnesium, colchicine, orlistat, GLP-1 agonists, SSRIs, PPIs, NSAIDs, antibiotics, mycophenolate, chemotherapy, immune checkpoint inhibitors

— Duodenum: iron, calcium, folate

— Jejunum: carbohydrate, fat, fat-soluble vitamins

— Terminal ileum: B12, bile acids (Crohn classic)

Board pearl: Fecal calprotectin is the single most useful outpatient test to distinguish IBD (elevated) from IBS (normal) — order it before empirically treating IBS in any patient with diarrhea-predominant symptoms, especially those with abdominal pain or systemic features.

"Buzzword" clinical pairings:

Quick mechanism associations:

Stool osmotic gap formula:

Drug-induced diarrhea offenders:

Vitamin deficiencies by site of malabsorption:

Board Question Stem Patterns

— Young woman with 6 months of cramping abdominal pain relieved by defecation, alternating stool consistency, no nocturnal symptoms, normal weight, normal CBC → Rome IV IBS-D; next step is limited workup (calprotectin, CBC, CRP, TTG-IgA) then trial of dietary modification and loperamide, NOT colonoscopy

— Same patient but with nocturnal diarrhea, weight loss, anemia → colonoscopy for IBD workup

— Older woman on PPI and SSRI with chronic watery nonbloody diarrhea, normal labs, grossly normal colonoscopy → stem hinges on knowing to do random biopsies; diagnosis = lymphocytic/collagenous colitis; treatment = budesonide + discontinue offending drugs

— Iron-deficiency anemia + diarrhea + bloating; or dermatitis herpetiformis → TTG-IgA + total IgA; confirm with EGD/duodenal biopsy; treatment = lifelong gluten-free diet

— Trap: starting gluten-free diet before serology

— Post-cholecystectomy or Crohn ileal resection patient with watery diarrhea → empiric cholestyramine trial = diagnostic and therapeutic

— Flushing + diarrhea + tricuspid regurgitation → 24-hour urine 5-HIAA; treat with octreotide

— Chronic alcoholic with weight loss + greasy stools → fecal elastase; treat with pancrelipase + ADEK supplementation

— Recent metformin initiation, GLP-1 agonist, colchicine, mycophenolate, or checkpoint inhibitor → identify culprit; for immune checkpoint inhibitor colitis → hold drug + high-dose steroids

— Young woman with hypokalemia, weight loss, melanosis coli → laxative abuse; psychiatric referral

— Recurrent diarrhea after antibiotic course; fidaxomicin for first recurrence; FMT after ≥2 recurrences

Key distinction: When the stem describes diarrhea + nocturnal symptoms, weight loss, anemia, or blood, the answer is never IBS — escalate to colonoscopy/biopsy and targeted serology rather than empiric symptomatic therapy.

Pattern 1 — IBS-D vs IBD:

Pattern 2 — Microscopic colitis:

Pattern 3 — Celiac disease:

Pattern 4 — Bile acid diarrhea:

Pattern 5 — Carcinoid:

Pattern 6 — Pancreatic insufficiency:

Pattern 7 — Drug-induced:

Pattern 8 — Surreptitious laxative abuse:

Pattern 9 — C. difficile recurrence:

One-Line Recap

Chronic diarrhea (>4 weeks) is approached by first ruling out medication and dietary causes, then classifying by mechanism — watery (secretory vs osmotic), fatty, or inflammatory — using stool osmotic gap, fecal calprotectin, fecal elastase, TTG-IgA, and basic labs to direct targeted endoscopy and treatment, while alarm features (age >50, blood, weight loss, anemia, nocturnal symptoms) mandate colonoscopy and exclude the IBS diagnosis.

— Fecal calprotectin distinguishes IBD from IBS; TTG-IgA + total IgA screens celiac

— Stool osmotic gap <50 = secretory (persists fasting), >100 = osmotic (improves fasting)

— Fecal elastase <200 confirms pancreatic insufficiency → pancrelipase + ADEK

— Random biopsies during colonoscopy are essential to diagnose microscopic colitis (normal-appearing mucosa)

— IBS-D: Rome IV criteria + limited labs → loperamide, low-FODMAP, rifaximin; never diagnose with nocturnal symptoms or weight loss

— Microscopic colitis: budesonide 9 mg + stop NSAIDs/PPIs/SSRIs

— Celiac: lifelong strict gluten-free diet + DEXA + nutrient replacement; serology before dietary trial

— Bile acid diarrhea (post-cholecystectomy): cholestyramine empirically diagnoses and treats

— Loperamide is contraindicated in suspected C. difficile, IBD flare, or bloody diarrhea

— Always exclude fecal impaction with overflow in elderly before initiating antidiarrheals

Step 3 management: Build the workup around mechanism and alarm features, not symptom severity — a focused first-tier panel (CBC, CMP, TSH, TTG-IgA, calprotectin, stool studies) plus a careful medication and dietary history resolves the majority of chronic diarrhea cases in the outpatient setting without invasive testing.

Top mechanism-driven workup pearls:

Top management pearls:

Top safety pearl: